Cardiff Oncology, Inc.

For the period ended Sep 30, 2026. Filed Nov 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 12, 2026

CRDF$0.73-4.9%Stored close · as of Nov 12, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

Checking your notes…

	Nine Months Ended September 30,
	2026	2025
Operating activities
Net loss	$(30,434)	$(38,635)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	262	276
Stock-based compensation expense	3,923	4,432
Amortization of right-of-use assets	404	405
Accretion of discounts on short-term investments, net	(181)	(690)
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivable	92	519
Prepaid expenses and other current assets	438	1,468
Other assets	(250)	(480)
Accounts payable and accrued liabilities	(7,614)	1,262
Operating lease liabilities	(567)	(513)
Net cash used in operating activities	(33,927)	(31,956)
Investing activities
Capital expenditures	(48)	(44)
Maturities of short-term investments	32,976	54,539
Purchases of short-term investments	(15,881)	(65,138)
Sales of short-term investments	2,086	1,236
Net cash provided by (used in) investing activities	19,133	(9,407)
Financing activities
Proceeds from sale of common stock and warrants	10,363	—
Payment of issuance costs	(1,085)	—
Proceeds from exercise of options	106	28
Net cash provided by financing activities	9,384	28
Net change in cash and cash equivalents	(5,410)	(41,335)
Cash and cash equivalents—Beginning of period	17,470	51,470
Cash and cash equivalents—End of period	$12,060	$10,135

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.